Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Compromise of gastric inhibitory polypeptide (GIP) receptor signalling represents a possible therapeutic strategy for the treatment of obesity-related diabetes. This study has characterised and evaluated the C-terminally fatty acid derivatised GIP analogues, GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal], as potential GIP inhibitors. Both GIP analogues lack the two N-terminal amino acids cleaved by DPP-4 and have addition of nine amino acids from the C-terminal of exendin(1-39), Cex. GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] effectively (p <0.01 to p <0.001) inhibited GIP-induced cAMP production and insulin secretion in vitro. In normal mice, GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] displayed a significant (p <0.05 to p <0.001) and prolonged inhibitory effect on GIP-induced glucose-lowering and insulin-releasing actions. When injected once daily for 21 days in obese-diabetic high fat fed mice, both GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] significantly reduced body weight (p <0.01 to p <0.001) and lowered circulating glucose (p <0.001) and insulin (p <0.01 to p <0.001) concentrations. The observed beneficial changes were independent of effects on energy intake, locomotor activity or metabolic rate. Oral and intraperitoneal glucose tolerance were significantly (p <0.05 to p <0.001) improved in both treatment groups at the end of the study, despite reduced glucose-induced plasma insulin concentrations. This improvement of metabolic control was accompanied by enhanced (p <0.05 to p <0.01) insulin sensitivity compared with high fat controls. These data demonstrate the potential offered by GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] for the treatment of obesity-related diabetes.
LanguageEnglish
Pages120-129
Number of pages10
JournalMolecular and Cellular Endocrinology
Volume401
Early online date6 Nov 2014
DOIs
Publication statusPublished - 5 Feb 2015

Fingerprint

Gastric Inhibitory Polypeptide
Lipoylation
Obesity
Fats
Insulin
Glucose
Amino Acids
Locomotion
Glucose Tolerance Test
Energy Intake
Insulin Resistance
Fatty Acids
Body Weight

Cite this

@article{957e0d407c9a4643bdb71abaa3fa9e90,
title = "Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice",
abstract = "Compromise of gastric inhibitory polypeptide (GIP) receptor signalling represents a possible therapeutic strategy for the treatment of obesity-related diabetes. This study has characterised and evaluated the C-terminally fatty acid derivatised GIP analogues, GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal], as potential GIP inhibitors. Both GIP analogues lack the two N-terminal amino acids cleaved by DPP-4 and have addition of nine amino acids from the C-terminal of exendin(1-39), Cex. GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] effectively (p <0.01 to p <0.001) inhibited GIP-induced cAMP production and insulin secretion in vitro. In normal mice, GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] displayed a significant (p <0.05 to p <0.001) and prolonged inhibitory effect on GIP-induced glucose-lowering and insulin-releasing actions. When injected once daily for 21 days in obese-diabetic high fat fed mice, both GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] significantly reduced body weight (p <0.01 to p <0.001) and lowered circulating glucose (p <0.001) and insulin (p <0.01 to p <0.001) concentrations. The observed beneficial changes were independent of effects on energy intake, locomotor activity or metabolic rate. Oral and intraperitoneal glucose tolerance were significantly (p <0.05 to p <0.001) improved in both treatment groups at the end of the study, despite reduced glucose-induced plasma insulin concentrations. This improvement of metabolic control was accompanied by enhanced (p <0.05 to p <0.01) insulin sensitivity compared with high fat controls. These data demonstrate the potential offered by GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] for the treatment of obesity-related diabetes.",
author = "V Pathak and Victor Gault and Peter Flatt and Nigel Irwin",
year = "2015",
month = "2",
day = "5",
doi = "10.1016/j.mce.2014.10.025",
language = "English",
volume = "401",
pages = "120--129",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier",

}

TY - JOUR

T1 - Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice

AU - Pathak, V

AU - Gault, Victor

AU - Flatt, Peter

AU - Irwin, Nigel

PY - 2015/2/5

Y1 - 2015/2/5

N2 - Compromise of gastric inhibitory polypeptide (GIP) receptor signalling represents a possible therapeutic strategy for the treatment of obesity-related diabetes. This study has characterised and evaluated the C-terminally fatty acid derivatised GIP analogues, GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal], as potential GIP inhibitors. Both GIP analogues lack the two N-terminal amino acids cleaved by DPP-4 and have addition of nine amino acids from the C-terminal of exendin(1-39), Cex. GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] effectively (p <0.01 to p <0.001) inhibited GIP-induced cAMP production and insulin secretion in vitro. In normal mice, GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] displayed a significant (p <0.05 to p <0.001) and prolonged inhibitory effect on GIP-induced glucose-lowering and insulin-releasing actions. When injected once daily for 21 days in obese-diabetic high fat fed mice, both GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] significantly reduced body weight (p <0.01 to p <0.001) and lowered circulating glucose (p <0.001) and insulin (p <0.01 to p <0.001) concentrations. The observed beneficial changes were independent of effects on energy intake, locomotor activity or metabolic rate. Oral and intraperitoneal glucose tolerance were significantly (p <0.05 to p <0.001) improved in both treatment groups at the end of the study, despite reduced glucose-induced plasma insulin concentrations. This improvement of metabolic control was accompanied by enhanced (p <0.05 to p <0.01) insulin sensitivity compared with high fat controls. These data demonstrate the potential offered by GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] for the treatment of obesity-related diabetes.

AB - Compromise of gastric inhibitory polypeptide (GIP) receptor signalling represents a possible therapeutic strategy for the treatment of obesity-related diabetes. This study has characterised and evaluated the C-terminally fatty acid derivatised GIP analogues, GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal], as potential GIP inhibitors. Both GIP analogues lack the two N-terminal amino acids cleaved by DPP-4 and have addition of nine amino acids from the C-terminal of exendin(1-39), Cex. GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] effectively (p <0.01 to p <0.001) inhibited GIP-induced cAMP production and insulin secretion in vitro. In normal mice, GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] displayed a significant (p <0.05 to p <0.001) and prolonged inhibitory effect on GIP-induced glucose-lowering and insulin-releasing actions. When injected once daily for 21 days in obese-diabetic high fat fed mice, both GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] significantly reduced body weight (p <0.01 to p <0.001) and lowered circulating glucose (p <0.001) and insulin (p <0.01 to p <0.001) concentrations. The observed beneficial changes were independent of effects on energy intake, locomotor activity or metabolic rate. Oral and intraperitoneal glucose tolerance were significantly (p <0.05 to p <0.001) improved in both treatment groups at the end of the study, despite reduced glucose-induced plasma insulin concentrations. This improvement of metabolic control was accompanied by enhanced (p <0.05 to p <0.01) insulin sensitivity compared with high fat controls. These data demonstrate the potential offered by GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] for the treatment of obesity-related diabetes.

UR - https://pure.ulster.ac.uk/en/publications/antagonism-of-gastric-inhibitory-polypeptide-gip-by-palmitoylatio-3

U2 - 10.1016/j.mce.2014.10.025

DO - 10.1016/j.mce.2014.10.025

M3 - Article

VL - 401

SP - 120

EP - 129

JO - Molecular and Cellular Endocrinology

T2 - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

ER -